Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.

McDonald PC, Chafe SC, Brown WS, Saberi S, Swayampakula M, Venkateswaran G, Nemirovsky O, Gillespie JA, Karasinska JM, Kalloger SE, Supuran CT, Schaeffer DF, Bashashati A, Shah SP, Topham JT, Yapp DT, Li J, Renouf DJ, Stanger BZ, Dedhar S.

Gastroenterology. 2019 Sep;157(3):823-837. doi: 10.1053/j.gastro.2019.05.004. Epub 2019 May 9.

2.

Spatially Specific Liposomal Cancer Therapy Triggered by Clinical External Sources of Energy.

van Ballegooie C, Man A, Win M, Yapp DT.

Pharmaceutics. 2019 Mar 16;11(3). pii: E125. doi: 10.3390/pharmaceutics11030125. Review.

3.

Inactivation of the Kinase Domain of CDK10 Prevents Tumor Growth in a Preclinical Model of Colorectal Cancer, and Is Accompanied by Downregulation of Bcl-2.

Weiswald LB, Hasan MR, Wong JCT, Pasiliao CC, Rahman M, Ren J, Yin Y, Gusscott S, Vacher S, Weng AP, Kennecke HF, Bièche I, Schaeffer DF, Yapp DT, Tai IT.

Mol Cancer Ther. 2017 Oct;16(10):2292-2303. doi: 10.1158/1535-7163.MCT-16-0666. Epub 2017 Jun 29.

4.

The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: treatment effects on metabolism, vascular function, cell proliferation, and tumor growth.

Yapp DT, Wong MQ, Kyle AH, Valdez SM, Tso J, Yung A, Kozlowski P, Owen DA, Buczkowski AK, Chung SW, Scudamore CH, Minchinton AI, Ng SS.

Angiogenesis. 2016 Apr;19(2):229-44. doi: 10.1007/s10456-016-9503-z. Epub 2016 Mar 9.

5.

Overexpression of HER-2 in MDA-MB-435/LCC6 Tumours is Associated with Higher Metabolic Activity and Lower Energy Stress.

Dragowska WH, Ginj M, Kozlowski P, Yung A, Ruth TJ, Adam MJ, Sossi V, Bally MB, Yapp DT.

Sci Rep. 2016 Jan 4;6:18537. doi: 10.1038/srep18537.

6.

Induction of Cytotoxicity in Pyridine Analogues of the Anti-metastatic Ru(III) Complex NAMI-A by Ferrocene Functionalization.

Mu C, Chang SW, Prosser KE, Leung AW, Santacruz S, Jang T, Thompson JR, Yapp DT, Warren JJ, Bally MB, Beischlag TV, Walsby CJ.

Inorg Chem. 2016 Jan 4;55(1):177-90. doi: 10.1021/acs.inorgchem.5b02109. Epub 2015 Dec 11.

PMID:
26652771
7.

Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.

Verreault M, Wehbe M, Strutt D, Masin D, Anantha M, Walker D, Chu F, Backstrom I, Kalra J, Waterhouse D, Yapp DT, Bally MB.

J Control Release. 2015 Dec 28;220(Pt A):348-357. doi: 10.1016/j.jconrel.2015.10.053. Epub 2015 Nov 1.

PMID:
26528901
8.

Nitroimidazole-Containing H2dedpa and H2CHXdedpa Derivatives as Potential PET Imaging Agents of Hypoxia with (68)Ga.

Ramogida CF, Pan J, Ferreira CL, Patrick BO, Rebullar K, Yapp DT, Lin KS, Adam MJ, Orvig C.

Inorg Chem. 2015 May 18;54(10):4953-65. doi: 10.1021/acs.inorgchem.5b00554. Epub 2015 Apr 30.

PMID:
25928800
9.

The involvement of insulin-like growth factor 2 binding protein 3 (IMP3) in pancreatic cancer cell migration, invasion, and adhesion.

Pasiliao CC, Chang CW, Sutherland BW, Valdez SM, Schaeffer D, Yapp DT, Ng SS.

BMC Cancer. 2015 Apr 11;15:266. doi: 10.1186/s12885-015-1251-8.

10.

Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.

Neijzen R, Wong MQ, Gill N, Wang H, Karim T, Anantha M, Strutt D, Waterhouse D, Bally MB, Tai IT, Ng SS, Yapp DT.

J Control Release. 2015 Feb 10;199:72-83. doi: 10.1016/j.jconrel.2014.11.031. Epub 2014 Dec 8.

PMID:
25497312
11.

A simple route to [11C]N-Me labeling of aminosuberic acid for proof of feasibility imaging of the x(C)⁻ transporter.

Yang H, Miao Q, Johnson BF, Rishel MJ, Sossi V, Dinelle K, Bénard F, Yapp DT, Webster JM, Schaffer P.

Bioorg Med Chem Lett. 2014 Dec 1;24(23):5512-5. doi: 10.1016/j.bmcl.2014.10.004. Epub 2014 Oct 13.

PMID:
25455495
13.

Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer.

Chittaranjan S, Bortnik S, Dragowska WH, Xu J, Abeysundara N, Leung A, Go NE, DeVorkin L, Weppler SA, Gelmon K, Yapp DT, Bally MB, Gorski SM.

Clin Cancer Res. 2014 Jun 15;20(12):3159-73. doi: 10.1158/1078-0432.CCR-13-2060. Epub 2014 Apr 10.

14.

Functional imaging of oxidative stress with a novel PET imaging agent, 18F-5-fluoro-L-aminosuberic acid.

Webster JM, Morton CA, Johnson BF, Yang H, Rishel MJ, Lee BD, Miao Q, Pabba C, Yapp DT, Schaffer P.

J Nucl Med. 2014 Apr;55(4):657-64. doi: 10.2967/jnumed.113.126664. Epub 2014 Feb 27.

15.

Increasing the bioavailability of Ru(III) anticancer complexes through hydrophobic albumin interactions.

Webb MI, Wu B, Jang T, Chard RA, Wong EW, Wong MQ, Yapp DT, Walsby CJ.

Chemistry. 2013 Dec 9;19(50):17031-42. doi: 10.1002/chem.201302671. Epub 2013 Nov 7.

PMID:
24203647
16.

Synthesis, characterization, and biological studies of emissive rhenium-glutamine conjugates.

Huang R, Langille G, Gill RK, Li CM, Mikata Y, Wong MQ, Yapp DT, Storr T.

J Biol Inorg Chem. 2013 Oct;18(7):831-44. doi: 10.1007/s00775-013-1023-3. Epub 2013 Aug 8.

PMID:
23925425
17.

Imaging tumor vasculature noninvasively with positron emission tomography and RGD peptides labeled with copper 64 using the bifunctonal chelates DOTA, oxo-DO3a. and PCTA.

Yapp DT, Ferreira CL, Gill RK, Boros E, Wong MQ, Mandel D, Jurek P, Kiefer GE.

Mol Imaging. 2013 Jun;12(4):263-72.

PMID:
23651504
18.

(68)Ga small peptide imaging: comparison of NOTA and PCTA.

Ferreira CL, Yapp DT, Mandel D, Gill RK, Boros E, Wong MQ, Jurek P, Kiefer GE.

Bioconjug Chem. 2012 Nov 21;23(11):2239-46. doi: 10.1021/bc300348d. Epub 2012 Oct 19.

PMID:
23035991
19.

RGD conjugates of the H2dedpa scaffold: synthesis, labeling and imaging with 68Ga.

Boros E, Ferreira CL, Yapp DT, Gill RK, Price EW, Adam MJ, Orvig C.

Nucl Med Biol. 2012 Aug;39(6):785-94. doi: 10.1016/j.nucmedbio.2012.01.003. Epub 2012 Mar 3.

PMID:
22381779
20.

Irinophore C™, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model.

Verreault M, Strutt D, Masin D, Anantha M, Waterhouse D, Yapp DT, Bally MB.

J Control Release. 2012 Feb 28;158(1):34-43. doi: 10.1016/j.jconrel.2011.09.095. Epub 2011 Oct 5.

PMID:
22001870
21.

Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine.

Verreault M, Strutt D, Masin D, Anantha M, Yung A, Kozlowski P, Waterhouse D, Bally MB, Yapp DT.

BMC Cancer. 2011 Apr 8;11:124. doi: 10.1186/1471-2407-11-124.

22.

Comparison of bifunctional chelates for (64)Cu antibody imaging.

Ferreira CL, Yapp DT, Crisp S, Sutherland BW, Ng SS, Gleave M, Bensimon C, Jurek P, Kiefer GE.

Eur J Nucl Med Mol Imaging. 2010 Nov;37(11):2117-26. doi: 10.1007/s00259-010-1506-1. Epub 2010 Jun 16.

PMID:
20552190
23.

Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma.

Cham KK, Baker JH, Takhar KS, Flexman JA, Wong MQ, Owen DA, Yung A, Kozlowski P, Reinsberg SA, Chu EM, Chang CW, Buczkowski AK, Chung SW, Scudamore CH, Minchinton AI, Yapp DT, Ng SS.

Br J Cancer. 2010 Jun 29;103(1):52-60. doi: 10.1038/sj.bjc.6605727. Epub 2010 Jun 8.

24.

Characterization of cationic liposome formulations designed to exhibit extended plasma residence times and tumor vasculature targeting properties.

Ho EA, Ramsay E, Ginj M, Anantha M, Bregman I, Sy J, Woo J, Osooly-Talesh M, Yapp DT, Bally MB.

J Pharm Sci. 2010 Jun;99(6):2839-53. doi: 10.1002/jps.22043.

PMID:
20091826
25.

Assessment of vessel size by MRI in an orthotopic model of human pancreatic cancer.

Flexman JA, Yung A, Yapp DT, Ng SS, Kozlowski P.

Conf Proc IEEE Eng Med Biol Soc. 2008;2008:851-4. doi: 10.1109/IEMBS.2008.4649287.

PMID:
19162790
26.

Evaluation of novel bifunctional chelates for the development of Cu-64-based radiopharmaceuticals.

Ferreira CL, Yapp DT, Lamsa E, Gleave M, Bensimon C, Jurek P, Kiefer GE.

Nucl Med Biol. 2008 Nov;35(8):875-82. doi: 10.1016/j.nucmedbio.2008.09.001.

PMID:
19026949
27.

Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin.

Baker JH, Lam J, Kyle AH, Sy J, Oliver T, Co SJ, Dragowska WH, Ramsay E, Anantha M, Ruth TJ, Adam MJ, Yung A, Kozlowski P, Minchinton AI, Ng SS, Bally MB, Yapp DT.

Clin Cancer Res. 2008 Nov 15;14(22):7260-71. doi: 10.1158/1078-0432.CCR-08-0736.

28.

In vivo measurement of the hypoxia marker EF5 in Shionogi tumours using (19)F magnetic resonance spectroscopy.

Hoff MN, Yapp DT, Yung AC, Oliver TS, Kozlowski P.

Int J Radiat Biol. 2008 Mar;84(3):237-42. doi: 10.1080/09553000801902174.

PMID:
18300024
29.

Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin.

Dragowska WH, Verreault M, Yapp DT, Warburton C, Edwards L, Ramsay EC, Huxham LA, Minchinton AI, Gelmon K, Bally MB.

Breast Cancer Res Treat. 2007 Dec;106(3):319-31. Epub 2007 Mar 9.

PMID:
17347776
30.

Non-invasive evaluation of tumour hypoxia in the Shionogi tumour model for prostate cancer with 18F-EF5 and positron emission tomography.

Yapp DT, Woo J, Kartono A, Sy J, Oliver T, Skov KA, Koch CJ, Adomat H, Dragowska WH, Fazli L, Ruth T, Adam MJ, Green D, Gleave M.

BJU Int. 2007 May;99(5):1154-60. Epub 2007 Feb 19. Erratum in: BJU Int. 2007 May;99(5):1161. Fadzli, Ladan [corrected to Fazli, Ladan].

31.

Hypoxia in the androgen-dependent Shionogi model for prostate cancer at three stages.

Skov K, Adomat H, Bowden M, Dragowska W, Gleave M, Koch CJ, Woo J, Yapp DT.

Radiat Res. 2004 Nov;162(5):547-53.

PMID:
15624309
32.

HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization.

Dragowska WH, Warburton C, Yapp DT, Minchinton AI, Hu Y, Waterhouse DN, Gelmon K, Skov K, Woo J, Masin D, Huxham LA, Kyle AH, Bally MB.

Mol Cancer Res. 2004 Nov;2(11):606-19.

35.

Tumor radiosensitization by sustained intratumoral release of bromodeoxyuridine.

Doiron A, Yapp DT, Olivares M, Zhu JX, Lehnert S.

Cancer Res. 1999 Aug 1;59(15):3677-81.

36.
37.

The potentiation of the effect of radiation treatment by intratumoral delivery of cisplatin.

Yapp DT, Lloyd DK, Zhu J, Lehnert SM.

Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):413-20.

PMID:
9788424
38.

Tumor treatment by sustained intratumoral release of cisplatin: effects of drug alone and combined with radiation.

Yapp DT, Lloyd DK, Zhu J, Lehnert SM.

Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):497-504.

PMID:
9308956

Supplemental Content

Support Center